NAMSA, a leading US-based medical device research organization, has announced the acquisition of Medvance Ltd., a clinical research and resourcing organization located in Yorkshire, England.
The addition of Medvance expands NAMSA’s MRO™ Approach to consulting and testing, adding dedicated support across the UK and continental Europe to NAMSA’s already successful global footprint in the US, Germany, France and China. NAMSA supports clients through all product development phases, from regulatory knowledge through non-clinical and clinical research and even postmarket products and services. By combining the two companies, NAMSA has experts in nearly every therapeutic area to accelerate product development, market approval and extend market acceptance in all major markets around the globe.
“Medvance clients will benefit from NAMSA’s deep expertise in biostatistics as well as their material scientists and biocompatibility experts,” said Medvance CEO Janette Benaddi. “In addition, NAMSA’s strength and relationships offer clients more insight into the US, Japan and China.” Janette Benaddi will remain part of the new NAMSA Medvance in a key executive role.